Spero Therapeutics, Inc. (SPRO): Total Assets
$68.92M
As of 2025-12-31
$52.77M
As of 2026-06-30
-18.0%
3-year compound annual growth
-14.8%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $68.92M | -37.7% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $110.54M | -39.4% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $182.39M | +46.1% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $124.80M | -27.0% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $171.07M | +11.5% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $153.45M | +44.6% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $106.10M | -17.8% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $129.01M | +38.0% | 2020-03-16, Balance as of period end |
| 2017-12-31 | $93.48M | +578.8% | 2019-03-14, Balance as of period end |
| 2016-12-31 | $13.77M | n/a | 2018-04-02, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $68.92M | -37.7% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $738.36M | -2.9% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $280.73M | -25.5% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $57.15M | -3.5% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $185.55M | +28.7% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $899.42M | +21.1% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $594.82M | +10.0% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $398.69M | +26.0% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $257.59M | +116.2% |
Compare SPRO, KURA, ENTA, RMTI side by side · Screen every company in Pharmaceutical Preparations ↗